Functional characterization of promoter region polymorphisms of human CYP2C19 gene

Molecular Biology Reports

Volumn 38, Issue 6, 2011, Pages 4171-4179

  Rao, Uppugunduri Satyanarayana Chakradhara ^a   Devendran, Anichavezhi ^a   Satyamoorthy, Kapettu ^b   Shewade, Deepak Gopal ^a   Krishnamoorthy, Rajgopal ^c   Chandrasekaran, Adithan ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b MANIPAL UNIVERSITY   (India)

^c HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Activating transcription factor 2; CCAAT displacement protein; CYP2C19; Electrophoretic mobility shift assay; Gene regulation; HepG2; Luciferase activity; Polymorphism; Promoter; Transcription

Indexed keywords

LUCIFERASE;

ARTICLE; BINDING SITE; CONTROLLED STUDY; CYP2C19 GENE; ENZYME ACTIVITY; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN BINDING; REPORTER GENE; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ARYL HYDROCARBON HYDROXYLASES; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENES, REPORTER; GENETIC LOCI; GENETIC VECTORS; HEP G2 CELLS; HUMANS; LUCIFERASES; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 80052483091     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0537-9     Document Type: Article

References (23)

1. Ingelman-Sundberg MA, Sim SC, Gomez A, Rodriguez AC (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526. doi:10.1016/j.pharmthera. 2007.09.004. (Pubitemid 350116943)
2. He N, Yan FX, Huang SL, Wang W, Xiao ZS, Liu ZQ, Zhou HH (2002) CYP2C19 genotype and S-mephenytoin 40-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol 58:15-18. doi:10.1007/s00228-002-0425-x. (Pubitemid 34327988)
3. Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958. doi:10.2165/00003088-20024 1120-00002. (Pubitemid 35168437)
4. Chang M, Dahl ML, Tybring G, Götharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358-363. doi:10.1097/00008571-199512000-00004. (Pubitemid 26011441)
5. Hoskins JM, Shenfield GM, Gross AS (2003) Concordance between proguanil phenotype and CYP2C19 genotype in Chinese. Eur J Clin Pharmacol 59:611-614. doi:10.1007/s00228- 003-0665-4. (Pubitemid 37494528)
6. Chang M, Tybring G, Dahl ML, Götharson E, Sagar M, Seensalu R, Bertilsson L (1995) Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39: 511-518.
7. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg MA (2006) Common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113. doi:10.1016/j.clpt.2005.10.002. (Pubitemid 43069582)
8. Arefayene M, Skaar TC, Zhao X, Rae JM, Tanus-Santos JE, Brinkmann U et al (2003) Sequence diversity and functional characterization of the 50 regulatory region of human CYP2C19. Pharmacogenetics 13:199-206. doi:10.1097/00008571-20030 4000-00004. (Pubitemid 36543392)
9. Satyanarayana CR, Devendran A, Sundaram R, Gopal SD, Rajagopal K, Chandrasekaran A (2009) Genetic variations and haplotypes of 50 regulatory region of CYP2C19 in South Indian population. Drug Metab Pharmacokinet 24:185-193. doi:10.2133/dmpk.24.185.
10. Pastinen T, Hudson TJ (2004) Cis-acting regulatory variation in the human genome. Science 306:647-650. doi:10.1126/science. 1101659. (Pubitemid 39440905)
11. Struhl K (1993) DNA-protein interactions. In: Ausbel F, Brent R, Kingston R, Mopre D, Seidman J, Smith J, Struhl K (eds) Current protocols in molecular biology. Wiley, New York, pp 4.9.1- 4.9.14.
12. Bradford MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254. doi: 10.1016/0003-2697(76)90527-3.
13. Satyanarayana CR, Devendran A, Jayaraman M, Mannu J, Mathur PP, Gopal SD, Rajagopal K, Chandrasekaran A (2009) Influence of the genetic polymorphisms in the 50 flanking and exonic regions of CYP2C19 on proguanil oxidation. Drug Metab Pharmacokinet 24:537-548. doi:10.2133/dmpk.24.537.
14. Antes TJ, Chen J, Cooper AD, Levy-Wilson B (2000) The nuclear matrix protein CDP represses hepatic transcription of the human cholesterol-7alpha hydroxylase gene. J Biol Chem 275:26649-26660. doi:10.1074/jbc.M002852200.
15. Mwinyi J, Hofmann Y, Pedersen RS, Nekvindová J, Cavaco I, Mkrtchian S, Ingelman-Sundberg M (2010) The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression. Life Sci 86:699-706. doi:10.1016/j.lfs.2010.02.021.
16. Shuman JD, Cheong J, Coligan JE (1997) ATF-2 and C/EBPalpha can form a heterodimeric DNA binding complex in vitro. Functional implications for transcriptional regulation. J Biol Chem 272:12793-12800. doi:10.1074/jbc.272.19. 12793. (Pubitemid 27203380)
17. Sher N, Yivgi-Ohana N, Orly J (2007) Transcriptional regulation of the cholesterol side chain cleavage cytochrome P450 gene (CYP11A1) revisited: binding of GATA, cyclic adenosine 30, 50- monophosphate response element-binding protein and activating protein (AP)-1 proteins to a distal novel cluster of cis-regulatory elements potentiates AP-2 and steroidogenic factor-1-dependent gene expression in the rodent placenta and ovary. Mol Endocrinol 21:948-962. doi:10.1210/me.2006-0226. (Pubitemid 46991957)
18. Kodama S, Moore R, Yamamoto Y, Negishi M (2007) Human nuclear pregnane X receptor cross-talk with CREB to repress cAMP activation of the glucose-6-phosphatase gene. Biochem J 407:373-381. doi:10.1042/BJ20070481. (Pubitemid 350058471)
19. Chen Y, Ferguson SS, Negishi M, Goldstein JA (2003) Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 64:316-324. doi:10.1124/mol.64.2.316. (Pubitemid 36909995)
20. Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM (2002) Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther 302:475-482. doi:10.1124/jpet.102.033837. (Pubitemid 34787209)
21. Feng HJ, Huang SL, Wang W, Zhou HH (1998) The induction effect of rifampicin on activity of mephenytoin 40-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 45:27-29. doi:10.1046/j.1365-2125. 1998.00643.x. (Pubitemid 28062850)
22. Chen Y, Goldstein JA (2009) The transcriptional regulation of the human CYP2C genes. Curr Drug Metab 10:567-578.
23. Kawashima S, Kobayashi K, Takama K, Higuchi T, Furihata T, Hosokawa M, Chiba K (2006) Involvement of hepatocyte nuclear factor 4alpha in the different expression level between CYP2C9 and CYP2C19 in the human liver. Drug Metab Dispos 34:1012- 1018. (Pubitemid 43763759)